Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response: 0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Source Moreice			2. Issuer Name and Ticker or Trading Symbol Praxis Precision Medicines, Inc. [PRAX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)									
Souza Marcio						Zame Transion medicines, me. [Third								X	Direc	tor	10% Owner		vner
(Last)	(Fi	rst) (f	Middle)		3. Da	Date of Earliest Transaction (Month/Day/Year)								X	Office below	er (give title /)		Other (s elow)	specify
C/O PRAXIS PRECISION MEDICINES, INC.						11/10/2020								Chief Executive Officer					
ONE BROADWAY, 16TH FLOOR																			
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street)														Line)					
CAMBR	IDGE M	A 0	2142											X Form filed by One Reporting Person Form filed by More than One Reporting					
															Perso		ie tilali Oli	е пер	Tung
(City)	(St	ate) (Z	Zip)																
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Benef	iciall	y Own	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			4 and Securit Benefic		ies cially Following	6. Owners Form: Dir (D) or Ind (I) (Instr. 4	ect rect	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) (D)	or Pr	ice	Transa	ction(s) 3 and 4)			(111341. 4)
Common Stock 11/10/2					2020				P		3,846	A	\$	26.08	.08 24,450		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
						a115, \	_					_		÷					
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any		4. Transaction Code (Instr. 8)		of Deriv	r osed) r. 3, 4	6. Date Expirat (Month	ion Da			8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Own Forn Direc or In (I) (Ir	ership i: et (D) direct estr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amou or Numb of Share	er					

Explanation of Responses:

Remarks:

/s/ Alex Nemiroff, as attorney-11/10/2020

in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.